Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
308
Total raised
£4.1B
disclosed amounts
This month
£27.8M
raised so far
The Cambridge-based biotechnology company secured the capital from a group of angel investors and Finance Wales.
"The early support we have received for our ideas and technologies from our angel investors and from Finance Wales has been very encouraging. We are delighted that this will allow us to maintain the very rapid momentum we have achieved in a short time."
The Greater Manchester spinout secured the capital from backers including The North West Fund for Biomedical and Central Manchester Foundation Trust to fund pre-clinical trials.
"Manchester is committed to its strategic and operational support for business growth and Co Angel Investment are just one of the services we have supported which is making a difference. We knew when we launched Co that Manchester held huge potential for a better, lower risk investment platform: the growing businesses like Gelexir are here, the Angels are here and now we have the infrastructure to bring them together to release further potential in the region."
The funding round was backed by Co Angel, The North West Fund for Biomedical, and the Central Manchester Foundation Trust.
"The team at Co have been instrumental as part of the process to date in giving strong and impartial advice, providing us links to potential investors, and generally supporting us in the fund raising process."
Longwall Venture Partners led the investment round, which will fund clinical trials and commercial development.
"closing this new investment round marks a significant step forward for UroSens. We are grateful to all of our investors for their continued support."
The funding was provided by Imperial Innovations, Cambridge Innovation Capital and Johnson & Johnson Development Corporation.
"This investment will secure the development of this technology in Cambridge and facilitate its translation into the clinic for the benefit of patients"
